Portal de Periódicos da CAPES

Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria

2012; Wiley; Volume: 25; Issue: 4 Linguagem: Inglês

10.1111/j.1529-8019.2012.01468.x

1529-8019

Takashi Hashimoto, Tamihiro Kawakami, Norito Ishii, Kaori Ishii, Tadashi Karashima, Takekuni Nakama, Daisuke Tsuruta, Teruki Dainichi, Michihiro Hide, Takahiro Hamada,

Coagulation, Bradykinin, Polyphosphates, and Angioedema

Dermatologic TherapyVolume 25, Issue 4 p. 379-381 Therapeutic Hotline Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria Takashi Hashimoto, Corresponding Author Takashi Hashimoto Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanCo-first authors.Address correspondence and reprint requests to: Takashi Hashimoto, MD, Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan, or email: [email protected].Search for more papers by this authorTamihiro Kawakami, Tamihiro Kawakami Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, JapanCo-first authors.Search for more papers by this authorNorito Ishii, Norito Ishii Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorKaori Ishii, Kaori Ishii Department of Dermatology, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorTadashi Karashima, Tadashi Karashima Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorTakekuni Nakama, Takekuni Nakama Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorDaisuke Tsuruta, Daisuke Tsuruta Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorTeruki Dainichi, Teruki Dainichi Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorMichihiro Hide, Michihiro Hide Department of Dermatology, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorTakahiro Hamada, Takahiro Hamada Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this author Takashi Hashimoto, Corresponding Author Takashi Hashimoto Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanCo-first authors.Address correspondence and reprint requests to: Takashi Hashimoto, MD, Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan, or email: [email protected].Search for more papers by this authorTamihiro Kawakami, Tamihiro Kawakami Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, JapanCo-first authors.Search for more papers by this authorNorito Ishii, Norito Ishii Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorKaori Ishii, Kaori Ishii Department of Dermatology, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorTadashi Karashima, Tadashi Karashima Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorTakekuni Nakama, Takekuni Nakama Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorDaisuke Tsuruta, Daisuke Tsuruta Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorTeruki Dainichi, Teruki Dainichi Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this authorMichihiro Hide, Michihiro Hide Department of Dermatology, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorTakahiro Hamada, Takahiro Hamada Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, JapanSearch for more papers by this author First published: 05 September 2012 https://doi.org/10.1111/j.1529-8019.2012.01468.xCitations: 11 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Chronic autoimmune urticaria is routinely diagnosed using an autologous serum skin test. Mizoribine is a newly developed immunosuppressive agent that has low toxicity. The pharmacological effects of mizoribine are similar to those of another purine biosynthesis inhibitor, mycophenolate mofetil. A 57-year-old woman presented with recurrent wheals and was insufficiently managed with administration of antihistamines, antileukotrienes, oral corticosteroids, and cyclosporine. She was positive in the autologous serum skin test. Oral mizoribine therapy was started as a combination therapy with prednisolone. The patient achieved a dramatic improvement in symptoms and complete resolution of the urticaria a few days after adding mizoribine to her treatment. The prednisolone was tapered after the start of mizoribine treatment. Her symptoms did not flare up, and no side effects were observed. In vitro basophil histamine release assays suggested that she might have anti-IgE autoantibody-type histamine release activity. We believe that mizoribine has a therapeutic role in some patients with chronic autoimmune urticaria and may be useful for treatment of cases not responsive to classical therapy. We suggest that mizoribine might help to reduce anti-IgE autoantibody acting on the surface of basophils in chronic autoimmune urticaria. References 1 Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998: 138: 635– 638. 2 Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic "idiopathic" urticaria. Br J Dermatol 2000: 143: 365– 372. 3 Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol 2003: 60: 390– 394. 4 Hide M, Tanaka T, Yamamura Y, Koro O, Yamamoto S. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol 2002: 82: 335– 340. 5 Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993: 328: 1599– 1604. Citing Literature Volume25, Issue4Special Issue: Evaluation and Treatment of Vascular DisordersJuly/August 2012Pages 379-381 ReferencesRelatedInformation